What Primex Pharmaceuticals does

Primex Pharmaceuticals is a privately-held, commercial-stage specialty pharmaceutical company focused on anesthesia and perioperative therapy, operating through three legal entities (Primex Pharmaceuticals Oy in Finland, Primex Pharmaceuticals AG in Switzerland as international headquarters, and Giovanni Ogna e Figli S.r.l in Italy). The company's product portfolio centers on two core platforms: Recofol, a propofol-based intravenous anesthetic acquired from Bayer in 2011 with MCT/LCT, EDTA-preserved, and veterinary formulations for anesthesia and ICU sedation; and OZALIN/OZASED, a 2mg/ml oral midazolam solution developed at Amiens Hospital in France and approved across 16 European countries as the only product indicated for pediatric procedural sedation (infants from 6 months through adolescents). The 2024 acquisition of Ogna added a nearly 90-year Italian dental pharmaceutical brand featuring local anesthetics (articaine, mepivicaine, lidocaine) and CE-marked endodontic medical devices. Manufacturing is fully outsourced, with EU-based production, while the company retains global regulatory, distribution, and marketing functions.

Primex operates an asset-light, partner-mediated go-to-market model in which regional partners serve as local Marketing Authorization Holders, sales, marketing, and distribution entities across 40+ countries spanning Europe, Mexico, Latin America, Southeast Asia (Indonesia), and MENA. The company generates revenue through branded generic product sales supplemented by licensing and regional divestiture transactions—most notably the 2024 European pediatric sedation rights divestiture designed to fund US and China expansion. Customer segments are diversified across hospitals/ICUs/surgical centers, pediatric healthcare providers, and dental practitioners, though all end-customer relationships are intermediated through the Primex Network of regional partners. The company turned profitable in 2012, has been funded by Finnish investors Bocap and Finnvera since 2014, and is currently led by CEO Tomaso Dameno (since end of 2023) with a leadership transition in 2024 bringing CFO Michael Augsberger and in 2025 appointing Bareket Gelbhart as Head of Business Development to lead an active partnering and investor outreach effort.

Name

Primex Pharmaceuticals

Legal name

Primex Pharmaceuticals consisting of Primex Pharmaceuticals Oy and its affiliates Primex Pharmaceuticals AG and Giovanni Ogna e Figli S.r.l

Website

https://primexpharma.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Primex Pharmaceuticals is a specialty pharmaceutical company developing and commercializing branded anesthesia (Recofol propofol), pediatric procedural sedation (OZALIN/OZASED oral midazolam), and dental products (OGNA), distributed through a regional partner network across 40+ countries for hospitals, pediatric care providers, and dental practitioners.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals (Anesthesia and Pediatric Sedation)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Generic Hospital & Institutional Products (HLAIABAL), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

• Anesthetic pharmaceuticals
• Pediatric sedation
• Perioperative therapy
• Branded generics
• Dental anesthetics

Headquarters

HQ city

Helsinki

HQ country

Finland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Product Sales: Sale of branded generic pharmaceutical products including Recofol (propofol-based anesthesia), OZALIN/OZASED (pediatric sedation), and OGNA dental products (local anesthetics, endodontic devices). Products sold through regional partner network across 40+ countries.
2. Licensing and Divestiture: European divestiture of pediatric sedation formulation rights completed in 2024, demonstrating strategy of developing and launching products then licensing or divesting regional rights to maximize value creation.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Primex Pharmaceuticals is a commercial-stage specialty pharmaceutical company that develops, registers and distributes branded generic anesthetic and pediatric sedation products, primarily Recofol (propofol-based IV anesthetics) and OZALIN/OZASED (oral midazolam solution for pediatric procedural sedation), alongside the Ogna dental anesthetic and endodontic portfolio. The company outsources manufacturing and leverages a regional partner network (the "Primex Network") across 40+ countries to serve as local MAH, sales, marketing and distribution partners.

Product overview

Primex Pharmaceuticals operates as an international commercial-stage specialty pharmaceutical company focused on anesthesia and perioperative therapy. The company offers a portfolio of branded generic anesthetic pharmaceuticals and innovative pediatric solutions through three integrated entities: Primex Pharmaceuticals Oy (Finland), Primex Pharmaceuticals AG (Switzerland), and Giovanni Ogna e Figli S.r.l (Italy). The product portfolio centers on two core platforms: Recofol (propofol-based IV anesthetic for anesthesia and ICU sedation available as standard MCT/LCT formulation, EDTA variant, and veterinary formulation) and OZALIN/OZASED (2mg/ml oral midazolam solution for pediatric procedural sedation). The Ogna acquisition added a nearly century-old dental portfolio featuring local anesthetics (articaine, mepivicaine, lidocaine) and CE-marked endodontic medical devices. The company outsources manufacturing and focuses on global regulatory affairs, distribution, and marketing through regional partnership networks spanning 40+ countries.

Differentiator

Problem solved

Functional benefit

Brands

• Recofol: Propofol-based products for anesthesia and ICU sedation, including Recofol N (MCT/LCT formulation), Recofol EDTA (propofol plus EDTA), and Propofo VET (for animals)
• OZALIN / OZASED
• OGNA Dental Portfolio

Products and services

• Recofol N Propofol intravenous anesthetic with MCT/LCT formulation acquired from Bayer in 2011, used by intensive care units, surgeries and clinics for anesthesia induction, maintenance of anesthesia and ICU sedation.
• Recofol EDTA Propofol formulation with EDTA as antimicrobial retardant preservative, compliant with FDA and other regulatory authority requirements. Manufactured in EU.
• OZALIN / OZASED 2mg/ml oral midazolam solution (formerly ADV6209) for pediatric procedural sedation. EU-approved for infants from 6 months, children and adolescents for moderate sedation before therapeutic or diagnostic procedures to relieve anxiety, distress and agitation. Developed at Amiens Hospital in France.
• Ogna Local Anaesthetic Portfolio Local anesthetic products including articaine, mepivicaine and lidocaine in spray and gel forms, from the nearly 90-year-old Italian dental pharmaceutical company Giovanni Ogna e Figli S.r.l.
• Ogna Endodontic Medical Devices CE-marked endodontic medical devices from the Ogna dental portfolio, used by dentists and dental surgeons for endodontic treatments.

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Mexican PartnercoreChannel Partner/ Reseller/ DistributorFifteen-year partnership with a 30,000-person Mexican organization. Despite size differential, this relationship has proven exceptional due to product uniqueness and strong personal relationships. One of the company's most successful partnerships.
• Ogna LaboratoricoreStrategic or Co-development PartnerItalian company specializing in dental products acquired by Primex. Nearly 90-year-old brand with exceptional market recognition in endodontics. Operates domestically in Italy while expanding internationally under its own brand. Products include local anesthetic portfolio (articaine, mepivicaine, lidocaine) and endodontic medical devices (CE marked).
• Safetots.orgminorGTM or Marketing PartnerNon-profit initiative of leading paediatric anaesthesiologists that promotes safe conduct of anaesthesia in children. Supported by unrestricted educational grant from Primex Pharmaceuticals.
• Troops SedationminorGTM or Marketing PartnerStandardized quality improvement tool from the International Committee for the Advancement of Procedural Sedation. Primex provides unrestricted educational grant support.

Scale indicators7 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Fresenius Kabi: Global leader in injectable anesthetics including a major propofol franchise. Direct competitor to Primex in propofol-based anesthesia and ICU sedation across hospital channels.
• Hikma Pharmaceuticals: Specialty generic injectable manufacturer with hospital-channel focus in anesthesia and sedation. Highly comparable business model of branded generics distributed through hospital and institutional customers across multiple regions.
• Aspen Pharmacare: Specialty pharma group that acquires and revitalizes branded generic portfolios globally, often in anesthesia and specialty hospital products. Closely mirrors Primex's acquire-revitalize-distribute playbook.

Emerging players

• Sintetica: Swiss specialty injectable pharmaceutical company with focus on anesthesia, analgesia, and CNS products. Direct overlap in hospital-channel injectable anesthetics and similar mid-sized European specialty profile.
• Paion AG: European specialty pharma developing and commercializing injectable anesthetic and sedation agents. Closely aligned with Primex's perioperative and procedural sedation therapeutic focus.
• Ethypharm: French specialty pharma focused on branded generics and specialty hospital products with European and international reach. Comparable French-anchored specialty pharma profile and partner distribution approach.
• Proveca: European specialty pharma dedicated to pediatric medicines. Directly comparable to Primex's pediatric sedation positioning and addresses similar unmet needs in pediatric formulations.

Broad incumbents

• Norgine: European specialty pharma with portfolio of branded specialty products distributed through partners across multiple regions. Similar partner-led European commercial model and acquisition-driven growth.
• Stada Arzneimittel: Large European generics and specialty pharma with broad hospital and consumer portfolio. Comparable in its mix of branded generics, specialty focus, and multi-country European presence.
• Almirall: European specialty pharma focused on dermatology and specialty hospital products with partner-led international expansion. Similar mid-sized European specialty pharma profile with bolt-on acquisition strategy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/primex-pharmaceuticals-ltd

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Primex Pharmaceuticals